Skip to main content

Table 2 Changes in FDG parameters and clinical parameters after treatment

From: Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?

Parameters Baseline After 6 months p value
FDG parameters
 Mean SUVmax 1.83 ± 0.34 1.90 ± 0.34 0.059
 TBR 1.71 ± 0.23 1.75 ± 0.29 0.222
Clinical parameters
 ESR (mm/h) 62.3 ± 32.2 36.5 ± 28.6 < 0.001
 CRP (mg/dL)a 1.3 (0.4–3.0) 0.1 (0.0–0.6) < 0.001
 MMP-3 (ng/mL)a 153.6 (70.5–412.6) 65.2 (39.3–133.4) < 0.001
 WBC (/μL) 6537.5 ± 2239.2 5609.4 ± 1992.5 < 0.001
 % neutrophils 68.7 ± 9.2 57.9 ± 12.7 < 0.001
 % eosinophils 2.3 ± 2.3 3.0 ± 2.6 0.004
 % basophils 0.4 ± 0.2 0.5 ± 0.3 < 0.001
 % monocytes 5.3 ± 1.8 6.3 ± 2.2 0.003
 % lymphocytes 22.2 ± 7.5 31.3 ± 11.6 < 0.001
 ACPA (U/mL)a 87.4 (12.1–100.0) 55.8 (8.0–100.0) 0.276
 ACPA positive, n (%) 34 (53.1) 29 (45.3) < 0.001
 RF (U/mL)a 49 (13–137) 27 (10–79) < 0.001
 RF positive, n (%) 34 (53.1) 25 (39.1) < 0.001
 DAS28-ESR 5.0 ± 1.2 3.3 ± 1.2 < 0.001
  1. The data are expressed as the mean ± standard deviation, with the exception of skewed variables (a), which are represented as medians (interquartile range)
  2. SUVmax maximum standardized uptake value; TBR tissue-to-background ratio; ESR erythrocyte sedimentation rate; CRP C-reactive protein; WBC white blood cell count; MMP-3 matrix metalloproteinase-3; ACPA anti-cyclic citrullinated peptide antibody; RF rheumatoid factor; DAS28 Disease Activity Score in 28 joints